DEF: Stereotaxis, Inc. Announces Details for 2025 Annual Meeting of Shareholders

Stereotaxis, Inc. has scheduled its Annual Meeting of Shareholders for May 15, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Stereotaxis, Inc. is holding its Annual Meeting of Shareholders on May 15, 2025, at its headquarters in St. Louis, Missouri.
• Shareholders will vote to elect two Class III directors to serve until the 2028 Annual Meeting.
• They will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2025 fiscal year.
• The record date for determining shareholders eligible to vote is March 17, 2025.
• As of the record date, there were 85,979,662 shares of common stock and 21,233 shares of Series A Convertible Preferred Stock outstanding.
• Each share of common stock entitles the holder to one vote, while each share of Series A Convertible Preferred Stock is entitled to 2,320 votes, subject to beneficial ownership limitations, resulting in a total of 107,643,405 votes.
• The Board of Directors recommends voting for the election of the director nominees and for the ratification of Ernst & Young LLP.
• Shareholders can vote via the Internet, telephone, or mail, with Internet and telephone voting closing on May 14, 2025, at 11:59 p.m. Eastern Daylight Time.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, reflecting a professional and compliant approach to corporate governance.

Positives

• The company is providing multiple avenues for shareholders to vote, including online, telephone, and mail.
• The Board is actively engaged in corporate governance, with independent directors and established committees.
• The company has a Code of Conduct and insider trading policy in place.
• The Audit Committee is composed of independent and financially sophisticated members.

Risks

• The document does not explicitly mention any specific risks facing the company.
• However, general business risks are inherent in any company's operations.

Future Outlook

The document outlines the procedures and proposals for the upcoming Annual Meeting of Shareholders, focusing on electing directors and ratifying the auditor, but does not provide specific forward-looking statements about the company's financial performance or strategic direction.

Management Comments

• David L. Fischel, Chief Executive Officer and Chairman of the Board, invites shareholders to attend the Annual Meeting and encourages them to vote.
• The Board thanks shareholders for their continued support.

Industry Context

This announcement is a standard corporate communication related to the governance of a publicly traded company. It does not provide specific insights into the competitive landscape or industry trends beyond the general context of Stereotaxis operating in the medical device sector.

Comparison to Industry Standards

• The director compensation program, with annual RSU awards of $200,000, is within the typical range for companies of similar size and industry.
• Companies like Intuitive Surgical and Profound Medical Corp., where some of Stereotaxis' directors hold or have held executive positions, serve as benchmarks for corporate governance and executive compensation practices in the medical device industry.
• The process for shareholder proposals and director nominations aligns with standard practices for publicly traded companies in the U.S.

Stakeholder Impact

• Shareholders are directly impacted by the decisions made at the Annual Meeting, including the election of directors and the ratification of the auditor.
• Employees are indirectly impacted through the overall governance and strategic direction of the company.
• The company's performance and governance practices can affect its relationships with customers, suppliers, and creditors.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Shareholders on May 15, 2025.
• The company will continue to operate under the oversight of the elected directors and the appointed auditor.

Key Dates

Keywords

shareholders, directors, proxy, voting, governance, compensation, audit, Stereotaxis, meeting